SB 239063
Tocris Bioscience | Catalog # 1962
Key Product Details
Description
Product Description
SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580 (Cat. Nos. 1202 and 1402). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
Licensing Information
Sold for research purposes under agreement from GlaxoSmithKline
Product Specifications for SB 239063
Molecular Weight
Formula
Storage
Purity
Chemical Name
CAS Number
PubChem ID
InChI Key
SMILES
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 3.68 | 10 with gentle warming |
Preparing Stock Solutions for SB 239063
The following data is based on the product molecular weight 368.41.
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 27.14 mL | 135.72 mL | 271.44 mL |
| 0.5 mM | 5.43 mL | 27.14 mL | 54.29 mL |
| 1 mM | 2.71 mL | 13.57 mL | 27.14 mL |
| 5 mM | 0.54 mL | 2.71 mL | 5.43 mL |
Calculators
Background References
References are publications that support the biological activity of the product. See our Citations tab to view 61 publications citing the usage of this product.
- Legos The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur.J.Pharmacol. 2002 PMID: 12106800
- Underwood SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J.Pharmacol.Exp.Ther. 2000 PMID: 10734180
- Barone SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J.Pharmacol.Exp.Ther. 2001 PMID: 11160612
Product Documents for SB 239063
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for SB 239063
For research use only
Citations for SB 239063
Customer Reviews for SB 239063 (1)
Have you used SB 239063?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Customer Images
-
Species: MouseAssay Type: In VitroCell Line/Tissue: Primary murine microglia cellsVerified Customer | Posted 06/08/2019The role of MAPK pathways (JNK, p38 and ERK) was studied in the LPA induced pro-inflammatory phenotype in microglia. In this case cells were incubated for the indicated time points with LPA (1µM) in the presence or absence of SB239063 (10µM) or SB203580 (10µM). A series of assays were performed. p38 MAPK inhibition totally decreased the expression of 4 pro-inflammatory transcription factors (here presented: pp65). Both inhibitors worked nicely and the results were consistent.
There are no reviews that match your criteria.